Published in final edited form as:

Free Radic Biol Med. 2012 July 15; 53(2): 230–236. doi:10.1016/j.freeradbiomed.2012.05.004.

Nitrated fibrinogen is a biomarker of oxidative stress in venous thromboembolism

Marissa Martinez¹, Adam Cuker², Angela Mills³, Richard Lightfoot¹, Yiyang Fan⁴, W. H. Wilson Tang⁵, Stanley L. Hazen⁵, and Harry Ischiropoulos^{1,*}

¹Departments of Pediatrics and Pharmacology, Children's Hospital of Philadelphia and the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA

²Department of Medicine, Raymond and Ruth Perelman School of Medicine University of Pennsylvania, Philadelphia, PA

³Department of Emergency Medicine, Raymond and Ruth Perelman School of Medicine University of Pennsylvania, Philadelphia, PA

⁴Department of Mathematics, Cleveland State University, Cleveland, OH

⁵Departments of Cell Biology and Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH

Abstract

The pathogenesis of venous thromboembolism (VTE) is linked to inflammation and oxidant production, although specific markers for these pathways with pathological relevance to VTE have not been explored. The coagulant protein fibrinogen is post-translationally modified by nitric oxide-derived oxidants to nitrated fibrinogen in both acute and chronic inflammatory states. Therefore, nitrated fibrinogen may serve as a marker of inflammation and oxidative stress in VTE. To test this hypothesis we enrolled subjects (n=251) presenting with suspected VTE at the Hospital of the University of Pennsylvania emergency department, 50 (19.9 %) of whom were positive by imaging or 90-day follow-up. Mean nitrated fibrinogen was elevated in VTE positive (62.7 nM, 95 % CI 56.6–68.8) compared to VTE negative patients (54.2 nM, 95 % CI 51.4–57.1; $P < 0.01$). Patients in the highest quartile of nitrated fibrinogen had an increased risk of VTE compared with patients in the lowest quartile (OR 3.30; 95 % CI 1.25–8.68; $P < 0.05$). This risk persisted after univariate adjustment for age, active cancer, and recent surgery, but not after multivariate adjustment. Mean fibrinogen levels measured either by the Clauss assay or by ELISA were not different between VTE negative and positive patients. These data indicate that nitrated fibrinogen is an oxidative risk marker in VTE, providing a novel mechanistic link between oxidant production, inflammation, and VTE.

Introduction

Venous thromboembolism (VTE) is a common thrombotic disease that encompasses both deep vein thrombosis (DVT) and pulmonary embolism (PE). VTE affects around 1 per 1000

© 2012 Elsevier Inc. All rights reserved.

*To whom correspondence should be addressed: Children's Hospital of Philadelphia Research Institute, 417 Abramson Research Center, 421 Curie Boulevard, Philadelphia, PA 19104-4318. ischirop@mail.med.upenn.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

people per year within the United States, with increasing incidence for congenital and acquired thrombophilic risk factors (1–3). VTE is a chronic disease with 30 % of patients experiencing a recurrent event over 10 years (4, 5), and is estimated to account for between 100,000 and 180,000 deaths each year (6). Thus, VTE represents a significant health problem that requires considerable attention.

The precise molecular and biochemical mechanisms of thrombus initiation in VTE remain unclear. Virchow proposed that changes in blood rheology, induction of a hypercoagulable state, or endothelial injury are conditions required for venous thrombosis (7). More recent studies indicate that inflammation plays an important role in VTE. However, the interplay between inflammation and Virchow's triad is still unresolved. One possibility is that components of the triad activate or damage endothelial cells within the vein wall resulting in upregulation of receptors for inflammatory and pro-coagulant molecules. Electron micrographs of early thrombus formation show leukocyte adhesion to the vein wall (8), presumably through the binding of P- and E-selectins that are expressed on activated endothelial cells (9, 10). Leukocytes shed tissue factor-bearing microparticles, which induce coagulation and the production of a fibrin clot (11). Neutrophils and monocytes, two of the most prevalent leukocytes in venous thrombi, are also able to generate nitrating intermediates, capable of lipid peroxidation and nitration of proteins (12, 13).

One protein known to be modified by tyrosine nitration is the coagulant protein fibrinogen. Upon activation of the coagulation cascade, circulating plasma fibrinogen is cleaved by thrombin to fibrin monomers, which polymerize to form a fibrin clot. Recent studies demonstrate an emerging role for nitrated fibrinogen that links inflammation and oxidant production to coagulation. Nitrated fibrinogen is elevated in the plasma of patients with coronary artery disease (CAD) and in smokers (14, 15). Additionally, in humans injected with small amounts of lipopolysaccharide, plasma levels of nitrated fibrinogen increase and remain elevated for at least 72 hrs post injection (16). This increase follows an elevation of circulating myeloperoxidase, an enzyme localized to the azurophilic granules of neutrophils, which is released during neutrophil activation and is capable of generating nitrating intermediates (12). Although these data suggest that nitrated fibrinogen plays a key role linking inflammation, oxidant production, and arterial thrombotic diseases, its role in VTE remains undefined. Moreover, nitrated fibrinogen is not simply a marker of inflammation and oxidative stress, but also has functional effects on fibrinogen and fibrin clotting. Fibrinogen nitration was shown to increase the rate of fibrin clot formation, diminish clot lysis rate, and alter fibrin clot structural and viscoelastic properties (14–16). These functional effects suggest that nitrated fibrinogen may represent a risk factor for increased thrombotic tendency during inflammation and oxidant stress. However, the levels of nitrated fibrinogen in VTE have not been ascertained. Herein we quantified the levels of nitrated fibrinogen in patients presenting to the emergency department with suspected VTE and evaluated if nitrated fibrinogen is a biochemical risk factor that could explain associations of oxidative stress and inflammation with thrombotic complications in VTE.

Materials and Methods

Patient population

We performed a prospective cohort study from January 2010 to March 2011 of consecutive subjects 18 years of age or older presenting to the Hospital of the University of Pennsylvania emergency department with suspected acute lower extremity DVT or PE. Exclusion criteria included history of VTE within the prior 4 weeks, unavailable for 90 day follow-up, and inability to provide informed consent. DVT was diagnosed by compression ultrasonography and PE by computed tomographic pulmonary angiography. Patients with negative imaging were contacted by telephone 90 days after enrollment to confirm that they did not develop

clinically apparent VTE. Those who reported development of VTE over this interval despite negative imaging were also considered positive for DVT and/or PE. Secondary variables were also collected including, demographic information, thrombotic risk factors, comorbidities, and medications. Prior to initiation of anticoagulant therapy in the emergency department, blood was collected from patients in 3.2 % sodium citrate (BD Vacutainer, Franklin Lakes, NJ). Blood was centrifuged at 150 g for 15 min, and the supernatant, platelet rich plasma, was transferred to a new tube. Platelet rich plasma was then centrifuged at 10,000 g for 10 min to obtain platelet poor plasma, followed by storage at -80°C for future analysis. Study design was approved by the Institutional Review Board Involving Human Subjects at the University of Pennsylvania and written informed consent was obtained from all study participants.

Plasma nitrated fibrinogen levels

Nitrated fibrinogen levels were measured in plasma using an ELISA described previously (16). Briefly, 96-well plates were coated with $10\text{ }\mu\text{g/ml}$ anti-nitrotyrosine antibodies generated and described elsewhere (17) in 50 mM carbonate buffer pH 9, and incubated at 4°C under constant rocking overnight. The next day, plates were washed with 50 mM Tris, 150 mM NaCl, 0.05 % Tween-20 (TBS-T). Plates were blocked with 3 % bovine serum albumin (BSA) (Roche Diagnostics, Mannheim, Germany) (wt/vol) in TBS-T for 2 h at 37°C , followed by incubation with 1 % BSA in TBS-T for 1 h at 37°C . A standard curve was created from purified fibrinogen (American Diagnostica, Stamford, CT) that had been chemically nitrated and the levels of nitration were independently determined (16). Plasma samples were diluted (1:10, 1:20) in 1 % BSA in TBS-T, added to the plate in duplicate and incubated 2 h at room temperature under constant rocking. Plates were washed with TBS-T and coated with $0.3\text{ }\mu\text{g/ml}$ HRP-conjugated rabbit-anti-human fibrinogen polyclonal antibody (DakoCytomation, Glostrup, Denmark) in 1 % BSA in TBS-T. After 2 h incubation at room temperature under gentle rocking, the plates were washed with TBS-T and developed with TMB substrate (KPL, Gaithersburg, MD) followed by quenching of the reaction with 2 M sulfuric acid (Fisher Scientific, Fair Lawn, NJ). The absorbance was measured at 405 nm (Molecular devices, Sunnyvale, CA). Nitrated fibrinogen values were normalized to quality control plasma run with each plate. Each patient sample was analyzed a minimum of three times and samples that exceeded 15 % coefficient of variation were excluded from analysis. The normalized mean intra-assay and inter-assay variations were 8.23 % and 9.32 %.

Plasma fibrinogen level

Fibrinogen levels were measured in plasma using an ELISA previously described (16). Ninety-six well plates (Maxisorb, Nunc, Rochester, NY) were coated with $10\text{ }\mu\text{g/ml}$ mouse anti-fibrinogen monoclonal antibody (16) in carbonate buffer pH 9, and incubated at 4°C , rocking overnight. The next day, plates were washed with TBS-T and blocked with 3 % BSA in TBS-T for 2 h at 37°C . A standard curve was created from purified fibrinogen (American Diagnostica, Stamford, CT) in TBS-T. Plasma was diluted (1:5000, 1:10000), added to the plate in triplicate, and incubated for 1 h 37°C . Plates were washed with TBS-T, then coated with $0.3\text{ }\mu\text{g/ml}$ HRP-conjugated rabbit-anti-human fibrinogen polyclonal antibody (DakoCytomation, Glostrup, Denmark) in 1% BSA in TBS-T and incubated 1 h at room temperature. The plate was developed with the TMB peroxidase substrate as described above. Fibrinogen values were normalized to quality control plasma run with each plate. The normalized mean intra-assay and inter-assay variations were 11.23% and 14.0%.

Plasma fibrinogen levels were measured by Clauss method (18) using a Destiny Max coagulation analyzer according to manufacturer's protocol (Trinity Biotech, Co. Wicklow, Ireland).

D-dimer

Plasma D-dimer levels were measured at the Hospital of the University of Pennsylvania coagulation laboratory using the Vidas® D-dimer exclusion assay™ (bioMérieux, Lyon, France). This assay measures the fibrin degradation product (FDP) D-dimer by an enzyme linked fluorescence assay. This sandwich ELISA based method uses two anti-FDP monoclonal antibodies (P10B5E12C9 and P2C5A10) coupled with fluorescence detection (19, 20). In accordance with the manufacturer's instructions, a D-dimer level <0.5 µg/ml was considered negative.

The laboratory personnel and technologists performing all assays were blinded to patient outcome. Laboratory results obtained on the archived plasma samples were not made available to clinicians or patients.

Statistics

Gaussian distribution was tested for all continuous variables using D'Agostino & Pearson omnibus normality test, which indicated non-parametric distributions for all variables within our data. Thus, comparisons between groups were made using Mann-Whitney U test. Nitrated fibrinogen, D-dimer, and fibrinogen are given as the mean and the 95 % confidence interval (CI). The adjusted model for nitrated fibrinogen levels was created using the generalized linear model, which accounted for demographics, comorbidities, and VTE risk factors. Odds ratios (OR) were compared by Fishers exact test. Trends in nitrated fibrinogen levels by quartile were compared by Chi-squared analysis. A P-value <0.05 was considered statistically significant. All statistical calculations were generated and analyzed using GraphPad Prism (GraphPad Software, La Jolla, CA), or R-Statistical package (<http://www.r-project.org/>).

Results

Patient characteristics

A total of 251 patients were enrolled in this study. Of the 83 subjects with suspected DVT, 18 had a positive ultrasound and an additional 3 were determined to be positive on 90-day follow-up. Among the 168 subjects with suspected PE, 28 had a positive computed tomographic pulmonary angiography and 1 additional patient was found to have new PE at 90 days. Patient demographics, disease history, risk factors, and medications are shown in Table 1. Three well-accepted risk factors for VTE were more prevalent in the VTE positive subset: advanced age, active cancer, and surgery within the past 6 weeks. VTE positive patients were significantly older compared with negative patients and were more likely to have active cancer or recent surgery. Thrombophilia testing was not performed as part of the study. Nevertheless, three patients reported a history of hereditary thrombophilia including one with protein C and two with protein S deficiency. Additionally, two patients reported having antiphospholipid syndrome. No other measured demographic variables, comorbidities, risk factors, or medication use differed between VTE positive and negative patients (Table 1).

Fibrinogen levels in VTE patients

Fibrinogen levels were quantified by ELISA, which measures fibrinogen antigen, and the Clauss assay, which measures fibrin clotting time. The mean levels of fibrinogen compared by Mann Whitney U test were not different between subjects with and without VTE by either Clauss assay or by ELISA (Figure 1A). Fibrinogen levels were also similar between DVT and PE patients irrespective of the assay employed (Clauss: DVT, n=17: 3.8 mg/ml, 95 % CI 3.0–4.6; PE, n=27: 4.5 mg/ml, 95 % CI 3.6–5.4; ELISA: DVT, n=21: 5.5 mg/ml, 4.4–6.5; PE, n=28: 5.6 mg/ml, 4.7–6.5) (Figure 1A). ELISA-determined fibrinogen levels were

higher than those reported by Clauss assay, which is consistent with findings in previous studies (21).

Nitrated fibrinogen levels in VTE patients

Nitrated fibrinogen was measured by an ELISA as described previously (16). The levels of nitrated fibrinogen were interpolated from a standard curve created with purified fibrinogen that was chemically nitrated and levels of nitration were independently determined (16). To ensure the integrity of each assay, every 96-well plate included a quality control plasma standard, and intra- and inter-assay variation did not exceed 15 %. The mean levels of nitrated fibrinogen were significantly higher in VTE positive compared to VTE negative patients (Figure 1B). Nitrated fibrinogen levels were not different between DVT and PE patients (DVT, n=17: 60.9 nM, 95 % CI 52.3–69.6; PE, n=27: 63.9 nM, 95 % CI 55.2–72.5). Previous data indicated that one functional effect of fibrinogen tyrosine nitration was increased rate of fibrin formation. Since the Clauss assay relies on fibrin clotting time in plasma to assess fibrinogen levels, Spearman correlation analysis was used to evaluate the relationship between nitrated fibrinogen and fibrinogen levels (Figure 1C). Nitrated fibrinogen correlated linearly with Clauss measured fibrinogen levels (n=207: $r=0.31$, 95 % CI 0.18–0.40; $P<0.000$).

D-dimer levels in VTE patients

D-dimers are fibrin degradation products that are produced in response to clot lysis by plasmin, and are used as a diagnostic marker for VTE (19, 22–25). D-dimer was measured with the Vidas® D-dimer exclusion assay™ according to manufacturer's instructions. As expected, mean D-dimer levels were significantly higher in VTE positive versus –VTE negative patients (Figure 1D).

Odds ratio for venous thromboembolism across increasing nitrated fibrinogen levels

Cubic spline curves with 95 % confidence intervals (CI) (n=226) were constructed to illustrate the relationship between nitrated fibrinogen levels and odds ratio of clinically documented VTE (Figure 2). This analysis shows a strong association between nitrated fibrinogen levels and increased risk for VTE ($P<0.005$). A similar relationship was found for rates of VTE across increasing nitrated fibrinogen quartiles (χ^2 for trend 7.69; $P<0.01$) (Table 2). Patients in the highest quartile were compared with those in the lowest quartile and were found to have an increased risk of VTE (Table 2). This risk was maintained after univariate adjustment for the risk factors found to be elevated in our VTE positive patient population: advanced age, active cancer, and recent surgery (Table 2, models 1, 2, and 3). However, multivariate analysis with these risk factors did not reach statistical significance (Table 2, model 4). This may reflect the small size of our VTE positive patient population, where additional adjustments reduce the final sample size and eliminate statistical significance.

Discussion

Previous studies have implied that inflammation and oxidative processes may be mechanistically linked to the pathogenesis of VTE (12–16, 26–31). Nitration of proteins and specifically, nitrated fibrinogen has been quantified in the plasma of subjects that experience inflammatory changes and oxidative burden (14–16). In this study the data indicate that oxidants, specifically nitrating intermediates produced in response to inflammation in VTE, result in nitration of fibrinogen. The levels of nitrated fibrinogen were significantly elevated in patients with acute VTE compared to those found to be negative for the disease. This increase was not dependent on changes in fibrinogen, as mean levels of fibrinogen were similar between the two groups. Based on previous studies, the levels of nitrated fibrinogen

in VTE negative patients are higher than would be expected in healthy non-smoking controls (14, 15). This is likely due to the presence of inflammatory and oxidative conditions in the VTE negative population, including CAD and smoking that are associated with increased plasma concentration of nitrated fibrinogen (14–16). Elevated levels of nitrated fibrinogen in VTE, CAD, and smokers suggest that inflammation and the production of nitric oxide-derived oxidants are present in thrombotic disorders as well as in those at risk for the disease. Previous research on the functional effects of nitration on fibrinogen indicates that this modification contributes to a prothrombotic phenotype (14, 15, 16). Thus, nitrated fibrinogen may serve as a comprehensive marker for activation of inflammatory pathways during thrombosis. Increasing nitrated fibrinogen levels were positively associated with risk of VTE. When compared with patients in the lowest quartile of nitrated fibrinogen, those in the highest quartile had a significantly increased risk of VTE. This relationship persisted after adjusting individually for the risk factors that were elevated in the VTE positive group: advanced age, active cancer, and recent surgery. However, this risk was not maintained after adjusting for the combined factors. The relatively small VTE positive patient group may account for this difference, whereby adjustment reduces the positive group sample size and eliminates statistical significance. A larger study would be needed to address this. The loss of significance in our multivariate regression analysis may also suggest that patients with more than one of these risk factors also have elevated nitrated fibrinogen levels independent of VTE. Earlier work has shown that nitrated proteins, including nitrated fibrinogen were significantly elevated in lung cancer patients (31). Further studies investigating nitrated fibrinogen in advanced age, various cancer types, and surgical patients would be necessary to evaluate these effects. Advanced age, malignancy, and the postoperative state are well-accepted risk factors for VTE (1, 33) and were more prevalent among VTE positive than negative subjects in our study. Other established risk factors were present in similar proportions among the two groups, possibly owing to the relatively small size of our study and the small number of patients harboring such risk factors.

In this study, nitrated fibrinogen was found to be elevated in the setting of acute VTE. It remains to be determined whether this elevation reflects an underlying mediator of VTE pathology or is merely a transient epiphenomenon of acute thrombosis. Studies in which nitrated fibrinogen levels are measured in patients at risk for VTE, as well as in the weeks and months following an event are needed to address this question, and may provide valuable information regarding VTE recurrence.

Previous work has revealed that fibrinogen is targeted for oxidative modifications *in vivo* (14–16, 31, 33). Tyrosine nitration even in the presence of other oxidized amino acids was shown to significantly accelerate clot formation and factor XIII cross-linking (14, 15). Incorporation of nitrated fibrinogen molecules into fibrin clots was documented by immune-electron microscopy and was found to alter clot architecture in a dose-dependent manner (14, 15). Changes in structure were accompanied by changes in viscoelastic properties and a decrease in dissolution by the fibrinolytic systems (14, 15). Removal of the nitrated fibrinogen molecules restored the kinetics of fibrin clot formation and architecture (15). These profound effects on fibrin clot structure were produced by a relative small fraction of fibrinogen molecules modified by nitration. Based on previous data and data reported herein, the yield of nitration represents 1–6 % of fibrinogen molecules (15). Kinetic analysis of fibrin formation revealed that insertion of nitrated fibrinogen molecules accelerated lateral aggregation, an event that follows the initial nucleation and the formation of half-staggered, double stranded protofibrils (36–38). This acceleration is likely due to increased “B-knob:b-hole” interactions, which are facilitated by the site specific nitration of two tyrosine residues near the b-hole of the β -chain (15). Overall, the concept that 1 nitrated molecule per 100 normal fibrinogen molecules can initiate the catalytic increase in lateral aggregation is intriguing and consistent with observations from other proteins that require

nucleation events to form protein fibers (39). These previous studies suggest that the elevated levels of nitrated fibrinogen in VTE positive patients would result in an increase in the kinetics of clot formation and subsequent changes in clot architecture. Additional studies are necessary to address this hypothesis.

In addition to nitrated fibrinogen, D-dimer levels were significantly elevated in VTE positive patients consistent with previous studies (19, 22–25). Sensitivity and specificity for D-dimer at 0.5 µg/ml cutoff in this patient population were 100 % (95 % CI 91.6–100) and 22.3 % (95 % CI 16.1–29.6), respectively and are similar to what has been previously reported for the Vidas® D-dimer exclusion assay™ (19, 25, 40).

Fibrinogen is an independent risk factor and predictor of CAD and associated morbidity and mortality (41, 42). However, its role in VTE remains unclear. The Leiden Thrombophilia Study (LETS) showed elevated fibrinogen levels measured by Clauss assay in DVT patients compared with healthy controls (43). However, in later investigations within LETS, increased risk of DVT with increasing fibrinogen levels was only found in patients >45 yrs. In patients <45 yrs, fibrinogen levels in the 95th percentile did not confer increased risk of DVT (44). Furthermore, in two separate studies in patients with suspected PE, the levels of fibrinogen were significantly lower in patients diagnosed as positive versus negative for the disease (45, 46). In this study, fibrinogen levels were similar between VTE positive and negative groups, and there were no differences in DVT versus PE patients. Patient population or sample size may account for the differences between this study and LETS, where DVT patients were compared to a large number of healthy age and sex-matched controls. Likewise, patient population may also explain the dissimilarity between this study and the two previous studies investigating fibrinogen in PE (45, 46).

Overall, fibrinogen nitration in the VTE subjects certainly reflects active inflammatory and oxidative states that could favor a pro-coagulant environment resulting in fibrin structures with altered biochemical and biophysical properties and structure. These alterations in fibrin clots may profoundly impact the pathology of VTE.

Acknowledgments

The work was supported by grants from the National Institutes of Health HL54926, HL103918 and ES013508 NIEHS Center of Excellence in Environmental Toxicology to HI, HL098055 and HL076491 to SLH, and HL103931 to WHT. MRM is supported by the Hemostasis and Thrombosis training grant T32 HL07971. HI is the Gisela and Dennis Alter Research Professor of Pediatric Neonatology at the Children's Hospital of Philadelphia Research Institute.

References

1. Anderson FA Jr, Wheeler HB, Goldberg RJ, Hosmer DW, Patwardhan NA, Jovanovic B, Forcier A, Dalen JE. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism; the Worcester DVT study. *Arch Intern Med.* 1991; 151:933–938. [PubMed: 2025141]
2. Salomon O, Steinberg DM, Zivelin A, Gitel S, Dardik R, Rosenberg N, Berliner S, Inbal A, Many A, Lubetsky A, Varon D, Martinowitz U, Seligsohn U. Single and combined prothrombotic factors in patients with idiopathic venous thromboembolism: Prevalence and risk assessment. *Arterioscler Thromb Vasc Biol.* 1999; 19:511–518. [PubMed: 10073951]
3. Pabinger I, Brucker S, Kyrle PA, Schneider B, Korninger HC, Niessner H, Lechner K. Hereditary deficiency of antithrombin III, protein C and protein S: Prevalence in patients with a history of venous thrombosis and criteria for rational patient screening. *Blood Coagul Fibrinolysis.* 1992; 3:547–553. [PubMed: 1450321]

4. Heit JA, Mohr DN, Silverstein MD, Petterson TM, O'Fallon WM, Melton LJ 3rd. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: A population-based cohort study. *Arch Intern Med.* 2000; 160:761–768. [PubMed: 10737275]
5. Schulman S, Lindmarker P, Holmstrom M, Larfars G, Carlsson A, Nicol P, Svensson E, Ljungberg B, Vierung S, Nordlander S, Leijd B, Jahed K, Hjorth M, Linder O, Beckman M. Post-thrombotic syndrome, recurrence, and death 10 years after the first episode of venous thromboembolism treated with warfarin for 6 weeks or 6 months. *J Thromb Haemost.* 2006; 4:734–742. [PubMed: 16634738]
6. US Department of Health and Human Services. Surgeon General's call to action to prevent deep vein thrombosis and pulmonary embolism. 2008.
7. Virchow, R. Thrombose und embolie. gefässentzündung und septische infektion. Frankfurt am Main: Von Meidinger & Sohn; 1856. p. 219-732.
8. Schaub RG, Simmons CA, Koets MH, Romano PJ 2nd, Stewart GJ. Early events in the formation of a venous thrombus following local trauma and stasis. *Lab Invest.* 1984; 51:218–224. [PubMed: 6748615]
9. Myers D Jr, Farris D, Hawley A, Wroblewski S, Chapman A, Stoolman L, Knibbs R, Strieter R, Wakefield T. Selectins influence thrombosis in a mouse model of experimental deep venous thrombosis. *J Surg Res.* 2002; 108:212–221. [PubMed: 12505044]
10. Geng JG, Bevilacqua MP, Moore KL, McIntyre TM, Prescott SM, Kim JM, Bliss GA, Zimmerman GA, McEver RP. Rapid neutrophil adhesion to activated endothelium mediated by GMP-140. *Nature.* 1990; 343:757–760. [PubMed: 1689464]
11. Hrachovinova I, Cambien B, Hafezi-Moghadam A, Kappelmayer J, Camphausen RT, Widom A, Xia L, Kazazian HH Jr, Schaub RG, McEver RP, Wagner DD. Interaction of P-selectin and PSGL-1 generates microparticles that correct hemostasis in a mouse model of hemophilia A. *Nat Med.* 2003; 9:1020–1025. [PubMed: 12858167]
12. Brennan ML, Wu W, Fu X, Shen Z, Song W, Frost H, Vadseth C, Narine L, Lenkiewicz E, Borchers MT, Lusis AJ, Lee JJ, Lee NA, Abu-Soud HM, Ischiropoulos H, Hazen SL. A tale of two controversies: Defining both the role of peroxidases in nitrotyrosine formation in vivo using eosinophil peroxidase and myeloperoxidase-deficient mice, and the nature of peroxidase-generated reactive nitrogen species. *J Biol Chem.* 2002; 277:17415–17427. [PubMed: 11877405]
13. Hazen SL, Zhang R, Shen Z, Wu W, Podrez EA, MacPherson JC, Schmitt D, Mitra SN, Mukhopadhyay C, Chen Y, Cohen PA, Hoff HF, Abu-Soud HM. Formation of nitric oxide-derived oxidants by myeloperoxidase in monocytes: Pathways for monocyte-mediated protein nitration and lipid peroxidation in vivo. *Circ Res.* 1999; 85:950–958. [PubMed: 10559142]
14. Vadseth C, Souza JM, Thomson L, Seagraves A, Nagaswami C, Scheiner T, Torbet J, Vilaire G, Bennett JS, Murciano JC, Muzykantov V, Penn MS, Hazen SL, Weisel JW, Ischiropoulos H. Prothrombotic state induced by post-translational modification of fibrinogen by reactive nitrogen species. *J Biol Chem.* 2004; 279:8820–8826. [PubMed: 14681238]
15. Parastatidis I, Thomson L, Burke A, Chernysh I, Nagaswami C, Visser J, Stamer S, Liebler DC, Koliakos G, Heijnen HF, Fitzgerald GA, Weisel JW, Ischiropoulos H. Fibrinogen beta-chain tyrosine nitration is a prothrombotic risk factor. *J Biol Chem.* 2008; 283:33846–33853. [PubMed: 18818200]
16. Heffron SP, Parastatidis I, Cuchel M, Wolfe ML, Tadesse MG, Mohler ER 3rd, Ischiropoulos H, Rader DJ, Reilly MP. Inflammation induces fibrinogen nitration in experimental human endotoxemia. *Free Radic Biol Med.* 2009; 47:1140–1146. [PubMed: 19631267]
17. Heijnen HF, van Donselaar E, Slot JW, Fries DM, Blachard-Fillion B, Hodara R, Lightfoot R, Polydoro M, Spielberg D, Thomson L, Regan EA, Crapo J, Ischiropoulos H. Subcellular localization of tyrosine-nitrated proteins is dictated by reactive oxygen species generating enzymes and by proximity to nitric oxide synthase. *Free Radic Biol Med.* 2006; 40:1903–1913. [PubMed: 16716892]
18. Clauss, A. Gerinnungsphysiologische schnellmethode zur bestimmung des fibrinogens.
19. de Moerloose P, Desmarais S, Bounameaux H, Reber G, Perrier A, Dupuy G, Pittet JL. Contribution of a new, rapid, individual and quantitative automated D-dimer ELISA to exclude pulmonary embolism. *Thromb Haemost.* 1996; 75:11–13. [PubMed: 8713772]

20. Perrier A, Desmarais S, Miron MJ, de Moerloose P, Lepage R, Slosman D, Didier D, Unger PF, Patenaude JV, Bounameaux H. Non-invasive diagnosis of venous thromboembolism in outpatients. *Lancet*. 1999; 353:190–195. [PubMed: 9923874]
21. Kallner A, Egberg N, Yu A, Merzoug-Djilali R, Blomberg I, Jorneskog G, Blomback M. Are results of fibrinogen measurements transferable? *Clin Chem Lab Med*. 2003; 41:804–808. [PubMed: 12880145]
22. Bounameaux H, Cirafici P, de Moerloose P, Schneider PA, Slosman D, Reber G, Unger PF. Measurement of D-dimer in plasma as diagnostic aid in suspected pulmonary embolism. *Lancet*. 1991; 337:196–200. [PubMed: 1670841]
23. Bozic M, Blinc A, Stegnar M. D-dimer, other markers of haemostasis activation and soluble adhesion molecules in patients with different clinical probabilities of deep vein thrombosis. *Thromb Res*. 2002; 108:107–114. [PubMed: 12590945]
24. Declerck PJ, Mombaerts P, Holvoet P, De Mol M, Collen D. Fibrinolytic response and fibrin fragment D-dimer levels in patients with deep vein thrombosis. *Thromb Haemost*. 1987; 58:1024–1029. [PubMed: 3127914]
25. Di Nisio M, Squizzato A, Rutjes AW, Buller HR, Zwinderman AH, Bossuyt PM. Diagnostic accuracy of D-dimer test for exclusion of venous thromboembolism: A systematic review. *J Thromb Haemost*. 2007; 5:296–304. [PubMed: 17155963]
26. Nordenholz KE, Mitchell AM, Kline JA. Direct comparison of the diagnostic accuracy of fifty protein biological markers of pulmonary embolism for use in the emergency department. *Acad Emerg Med*. 2008; 15:795–799. [PubMed: 19244629]
27. Wakefield TW, Strieter RM, Wilke CA, Kadell AM, Wroblewski SK, Burdick MD, Schmidt R, Kunkel SL, Greenfield LJ. Venous thrombosis-associated inflammation and attenuation with neutralizing antibodies to cytokines and adhesion molecules. *Arterioscler Thromb Vasc Biol*. 1995; 15:258–268. [PubMed: 7749835]
28. Henke PK, Varga A, De S, Deatrick CB, Eliason J, Arenberg DA, Sukheepod P, Thanaporn P, Kunkel SL, Upchurch GR Jr, Wakefield TW. Deep vein thrombosis resolution is modulated by monocyte CXCR2-mediated activity in a mouse model. *Arterioscler Thromb Vasc Biol*. 2004; 24:1130–1137. [PubMed: 15105284]
29. Lo SK, Cheung A, Zheng Q, Silverstein RL. Induction of tissue factor on monocytes by adhesion to endothelial cells. *J Immunol*. 1995; 154:4768–4777. [PubMed: 7536780]
30. Eiserich JP, Hristova M, Cross CE, Jones AD, Freeman BA, Halliwell B, van der Vliet A. Formation of nitric oxide-derived inflammatory oxidants by myeloperoxidase in neutrophils. *Nature*. 1998; 391:393–397. [PubMed: 9450756]
31. Pignatelli B, Li CQ, Boffetta P, Chen Q, Ahrens W, Nyberg F, Mukeria A, Bruske-Hohlfeld I, Fortes C, Constantinescu V, Ischiropoulos H, Ohshima H. Nitrated and oxidized plasma proteins in smokers and lung cancer patients. *Cancer Res*. 2001; 61:778–784. [PubMed: 11212282]
32. Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ 3rd. Risk factors for deep vein thrombosis and pulmonary embolism: A population-based case-control study. *Arch Intern Med*. 2000; 160:809–815. [PubMed: 10737280]
33. Parastatidis I, Thomson L, Fries DM, Moore RE, Tohyama J, Fu X, Hazen SL, Heijnen HF, Dennehy MK, Liebler DC, Rader DJ, Ischiropoulos H. Increased protein nitration burden in the atherosclerotic lesions and plasma of apolipoprotein A-I deficient mice. *Circ Res*. 2007; 101:368–376. [PubMed: 17615369]
34. Inada Y, Hessel B, Blomback B. Photooxidation of fibrinogen in the presence of methylene blue and its effect on polymerization. *Biochim Biophys Acta*. 1978; 532:161–170. [PubMed: 620051]
35. Shacter E, Williams JA, Levine RL. Oxidative modification of fibrinogen inhibits thrombin-catalyzed clot formation. *Free Radic Biol Med*. 1995; 18:815–821. [PubMed: 7750804]
36. Doolittle RF, Pandi L. Binding of synthetic B knobs to fibrinogen changes the character of fibrin and inhibits its ability to activate tissue plasminogen activator and its destruction by plasmin. *Biochemistry*. 2006; 45:2657–2667. [PubMed: 16489759]
37. Geer CB, Tripathy A, Schoenfisch MH, Lord ST, Gorkun OV. Role of 'B-b' knob-hole interactions in fibrin binding to adsorbed fibrinogen. *J Thromb Haemost*. 2007; 5:2344–2351. [PubMed: 17892530]

38. Litvinov RI, Gorkun OV, Galanakis DK, Yakovlev S, Medved L, Shuman H, Weisel JW. Polymerization of fibrin: Direct observation and quantification of individual B:b knob-hole interactions. *Blood*. 2007; 109:130–138. [PubMed: 16940416]
39. Hodara R, Norris EH, Giasson BI, Mishizen-Eberz AJ, Lynch DR, Lee VM, Ischiropoulos H. Functional consequences of alpha-synuclein tyrosine nitration: diminished binding to lipid vesicles and increased fibril formation. *J Biol Chem*. 2004; 279:47746–47753. [PubMed: 15364911]
40. Freyburger G, Trillaud H, Labrousse S, Gauthier P, Javorschi S, Bernard P, Grenier N. D-dimer strategy in thrombosis exclusion--a gold standard study in 100 patients suspected of deep venous thrombosis or pulmonary embolism: 8 DD methods compared. *Thromb Haemost*. 1998; 79:32–37. [PubMed: 9459318]
41. Benderly M, Graff E, Reicher-Reiss H, Behar S, Brunner D, Goldbourt U. Fibrinogen is a predictor of mortality in coronary heart disease patients. the bezafibrate infarction prevention (BIP) study group. *Arterioscler Thromb Vasc Biol*. 1996; 16:351–356. [PubMed: 8630658]
42. Folsom AR, Wu KK, Rosamond WD, Sharrett AR, Chambless LE. Prospective study of hemostatic factors and incidence of coronary heart disease: The atherosclerosis risk in communities (ARIC) study. *Circulation*. 1997; 96:1102–1108. [PubMed: 9286936]
43. Koster T, Rosendaal FR, Reitsma PH, van der Velden PA, Briet E, Vandenbroucke JP. Factor VII and fibrinogen levels as risk factors for venous thrombosis. A case-control study of plasma levels and DNA polymorphisms--the leiden thrombophilia study (LETS). *Thromb Haemost*. 1994; 71:719–722. [PubMed: 7974338]
44. van Hylckama Vlieg A, Rosendaal FR. High levels of fibrinogen are associated with the risk of deep venous thrombosis mainly in the elderly. *J Thromb Haemost*. 2003 Dec; 1(12):2677–2678. [PubMed: 14675106]
45. Kucher N, Kohler HP, Dornhofer T, Wallmann D, Lammle B. Accuracy of D-dimer/fibrinogen ratio to predict pulmonary embolism: A prospective diagnostic study. *J Thromb Haemost*. 2003; 1:708–713. [PubMed: 12871404]
46. Kucher N, Schroeder V, Kohler HP. Role of blood coagulation factor XIII in patients with acute pulmonary embolism. correlation of factor XIII antigen levels with pulmonary occlusion rate, fibrinogen, D-dimer, and clot firmness. *Thromb Haemost*. 2003; 90:434–438. [PubMed: 12958612]

Research Highlights

- Nitrated fibrinogen levels are higher in VTE positive versus VTE negative subjects.
- Risk of VTE increased in the highest quartile of nitrated fibrinogen.
- Nitrated fibrinogen is a marker of inflammation and oxidative stress in VTE.

Figure 1. Fibrinogen, nitrated fibrinogen and D-dimer levels in VTE negative and positive patients

A) Plasma fibrinogen levels were measured by two methods: ELISA, which measures fibrinogen antigen (VTE positive (+VTE), n=49: 5.5 mg/ml, 95 % CI 4.9–6.2; VTE negative (–VTE), n=194: 5.0 mg/ml, 95 % CI 4.7–5.3) and Clauss assay which measures fibrin clotting time (+VTE, n=44: 4.3 mg/ml, 95 % CI 3.6–4.9; –VTE, n=185: 4.0 mg/ml, 95 % CI 3.8–4.2). Mean fibrinogen levels for each assay were compared by Mann Whitney U test, P=non significant for both comparisons. B) Nitrated fibrinogen levels measured by ELISA were elevated in +VTE (n=48) as compared to –VTE (n=178) patients (62.7 nM, 95 % CI 56.6–68.8 vs. 54.2 nM, 95 % CI 51.4–57.1). Nitrated fibrinogen levels were compared by Mann Whitney U test, * P<0.01. C) Spearman's rank correlation analysis was used to evaluate the relationship between nitrated fibrinogen and Clauss-measured fibrinogen levels (n=207: r=0.31, 95 % CI 0.18–0.40; P<0.0001). D) D-dimer levels measured by Vidas® D-dimer exclusion assay™ were higher in +VTE (n=42) versus –VTE (n=157) patients (4.22 µg/ml, 95 % CI 3.23–5.20 vs. 1.42 µg/ml, 95 % CI 1.20–1.63). D-dimer levels were compared by Mann Whitney U test, **P<0.001. Data for panels A, B, and D are represented in box and whisker plots where the mid line is the median, the bottom and top of the boxes represent the 25th and 75th percentiles respectively, and lower and upper bars represent the 5th and 95th percentiles, respectively.

Figure 2. Relationship between the odds ratio of acute VTE and nitrated fibrinogen levels
Cubic spline regression model of the odds ratio of acute VTE as a function of nitrated fibrinogen after adjustment for comorbidity, demographics, and risk factors (n=226). Dotted lines represent the 95 % CI. $P < 0.005$.

Table 1

Characteristics of VTE patient population

	Non-VTE (n=201)	VTE (n=50)	P value
Age (yr)	47.6 ± 16.7	53.3 ± 16.4	0.0206 [*]
Gender (% male)	63 (31.3 %)	23 (46.0 %)	
BMI (Kg/m ²)	31.4 ± 9.2	28.9 ± 6.7	
Race and ethnicity			
Caucasian	75 (37.3 %)	26 (52.0 %)	
African American	121 (60.2 %)	22 (44.0 %)	
Other	5 (2.5 %)	2 (4.0 %)	
Hispanic	6 (3.0 %)	2 (4.0 %)	
Disease history and risk factors			
H/O DVT	35 (17.4 %)	9 (18.0 %)	
H/O PE	28 (13.9 %)	7 (14.0 %)	
H/O CAD/MI/Angina	15 (8.2 %)	5 (6.8 %)	
H/O stroke	15 (7.5 %)	4 (8.0 %)	
Liver disease	9 (4.5 %)	2 (4.0 %)	
Lupus	8 (4.0 %)	0 (0.0 %)	
Rheumatoid arthritis	4 (2.0 %)	1 (2.0 %)	
Peripheral artery disease	5 (2.5 %)	4 (8.0 %)	
Active cancer	38 (18.9 %)	19 (38.0 %)	0.0075 [‡]
Recent surgery [^]	26 (12.9 %)	15 (30.0 %)	0.0089 [‡]
Immobilization > 6 weeks	30 (14.9 %)	11 (22.0 %)	
Air travel [^]	4 (2.0 %)	2 (4.0 %)	
Tobacco use	77 (38.3 %)	17 (34.0 %)	
Pregnancy	5 (2.5 %)	4 (8.0 %)	
Trauma	11 (5.5 %)	3 (6.0 %)	
Infection	19 (9.5 %)	5 (10.0 %)	
Medications			
Antiplatelet	32 (15.9 %)	8 (16.0 %)	
Anticoagulant	25 (12.4 %)	8 (16.0 %)	
Statins	36 (17.9 %)	11 (22.0 %)	
Hormonal contraception	9 (4.5 %)	4 (8.0 %)	
Hormone therapy	1 (0.5 %)	1 (2.0 %)	
Antioxidants	6 (3.0 %)	3 (6.0 %)	
Immunosuppressants	29 (14.4 %)	4 (8.0 %)	

Values shown are mean ± SD or the number and percentage of sample group. VTE composition: DVT n=21; PE n=29.

^{*} Age and BMI were compared by Mann Whitney U test.

[‡] All other variables were compared by Fischer's exact test.

[^] Within past 6 weeks.

Table 2

Odds ratio of VTE by quartiles of nitrated fibrinogen

Quartiles	1	2	3	4
Nitrated fibrinogen	<43.5	43.5–54.1	54.1–69.6	369.7
–VTE	50	47	42	39
+VTE	7	9	14	18
Event rate	12.3 %	16.1 %	25.0 %	31.6 %
Unadjusted OR	1	1.37 (0.47–3.97)	2.38 (0.88–6.44)	3.30 (1.25–8.68) [†]
Adjusted OR (1)	1	1.30 (0.44–3.81)	2.22 (0.81–6.08)	3.25 (1.23–8.64) [†]
Adjusted OR (2)	1	1.37 (0.47–4.02)	2.42 (0.88–6.62)	2.84 (1.06–7.62) [†]
Adjusted OR (3)	1	1.26 (0.43–3.71)	2.23 (0.82–6.11)	2.84 (1.06–7.62) [†]
Adjusted OR (4)	1	1.21 (0.40–3.62)	2.17 (0.78–6.03)	2.55 (0.92–7.01)

Values listed as OR (95 % CI).

Model 1: Adjusted for age.

Model 2: Adjusted for cancer.

Model 3: Adjusted for surgery.

Model 4: Adjusted for age, cancer, surgery.

Odds ratios were compared by Fischer's exact test.

[†]
P<0.05